Working Together to Find a Cure     Print Page | Close Window

Press Release

Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences

Company CEO to Co-Chair Symposium being held on April 11th in NYC

NEW YORK and CLEVELAND, April 05, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, is pleased to announce a Gene Therapy for Rare Diseases Symposium with the New York Academy of Sciences (NYAS) and the Biochemical Pharmacology Discussion Group in New York City on April 11th, 2017.   

“We are pleased to co-host this unique gene therapy symposium that highlights the importance of outcome measurements in gene therapy trial design, preclinical strategies, new clinical redosing paradigms and combination approaches for treating rare diseases,” stated Timothy J. Miller, PhD, President & CEO of Abeona Therapeutics.

Website & Webinar Link: http://www.nyas.org/RareDiseases

About New York Academy of Sciences: The New York Academy of Sciences (NYAS) is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 25,000 members around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org.

About the Biochemical Pharmacology Discussion Group: The Biochemical Pharmacology Discussion Group represents a diverse group of scientists from pharmaceutical and biotechnology companies and university and medical research centers interested in biochemistry, molecular biology, biomedical research, and related areas. The group brings together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development. The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Chapter.

About Abeona: Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com

Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com

Primary Logo

Abeona Therapeutics Inc